In vitro reactivity of allospecific cytotoxic T lymphocytes does not explain the taboo phenomenon

Transplant Immunology

Volumn 7, Issue 4, 1999, Pages 215-220

  Stobbe, Inge ^a   Van Der Meer Prins, Ellen ^a   Smits, Jacqueline MA ^a   Doxiadis, Ilias IN ^a   Claas, Frans HJ ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CD8 ANTIGEN; CYCLOSPORIN A; HLA A ANTIGEN; OKT 8; SYNTHETIC PEPTIDE;

ANTIGEN BINDING CELL; ARTICLE; BIOASSAY; COMPETITIVE INHIBITION; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; HLA MATCHING; HUMAN; HUMAN CELL; KIDNEY ALLOGRAFT REJECTION; KIDNEY TUBULE CELL; LYMPHOCYTE ACTIVATION; MONONUCLEAR CELL; PRIORITY JOURNAL; STEM CELL; TARGET CELL;

EID: 0033401435     PISSN: 09663274     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0966-3274(99)80005-7     Document Type: Article

References (45)

1. Opelz G, Terasaki PI. Studies on the strength of HLA antigens in related donor kidney transplantation. Transplantation. 24:1977;106-111.
2. Opelz G. Importance of HLA antigen splits for kidney transplant matching. Lancet. 2:1988;61-64.
3. Thorogood J, Persijn GG, Schreuder GM, et al. The effect of HLA matching on kidney graft survival in separate post-transplantation intervals. Transplantation. 50:1990;146-150.
4. Gjertson DW, Terasaki PI, Takemoto S, Mickey MR. National allocation of cadaveric kidneys by HLA matching. Projected effect on outcome and costs. N Engl J Med. 324:1991;1032-1036.
5. van Rood JJv, Lagaaij EL, Doxiadis I, et al. Permissible mismatches, acceptable mismatches, and tolerance: new trends in decision making. Terasaki PI, Cecka JM. Clinical transplants. 1993;285-292 UCLA Tissue Typing, Los Angeles, CA.
6. Benacerraf B. Role of MHC gene products in immune regulation. Science. 212:1981;1229-1238.
7. Hsu SH, Chan MM, Bias WB. Genetic control of major histocompatibility complex-linked immune responses to synthetic polypeptides in man. Proc Natl Acad Sci USA. 78:1981;440-444.
8. Moller G. HLA and disease susceptibility. Immunol Rev. 70:1983;113-155.
9. Vries RRPD, van Eden W, Ottenhof THM. HLA class II immune response genes and products in leprosy. Prog Allergy. 36:1985;95-113.
10. Busson M, Gony J, Hors J. Is the strength of single HLA antigen mismatch variable in kidney transplant survival? Transplantation. 28:1979;313-315.
11. Hendriks GFJ, Schreuder GMTh, Claas FHJ, et al. HLA-DRw6 and renal allograft rejection. BMJ. 286:1983;85-87.
12. Hendriks GFJ, D'Amaro J, Persijn GG. Excellent outcome after transplantation of renal allografts from HLA-DRw6-positive donors even in HLA-DR mismatches. Lancet. ii:1983;187-188.
13. Dyer PA, Martin S, Kippax R, Mallick NP, Gokal R, Johnson RWG. HLA-DR3 is a marker of graft failure in cadaveric renal transplantation. Transplant Proc. 17:1985;2248-2249.
14. Dobbe CM, Thorogood J, de Lange P, D'Amaro J, Persijn GG, Giphart MJ. An unexpected effect of matching for HLA-A9 in renal transplantation. Transplantation. 50:1990;446-448.
15. Goulmy E, Poel JJvd, Giphart M. The influence of HLA-A2 subtype mismatch on renal allograft survival. Transplantation. 53:1992;1381-1382.
16. Alamartine E, Berthouz F, Acquart S, Lepetit JC. Influence of HLA antigens of renal transplant recipients on graft survival. Transplant Proc. 24:1992;2461-2462.
17. Soulillou JP, Bignon JD. Poor kidney graft survival in recipients with HLA-DRw6. N Engl J Med. 308:1983;969.
18. Forsberg B, Ekberg H, Johnson U. Influence of recipient's HLA type on the outcome of renal transplantation. Transplant Proc. 24:1992;2463-2465.
19. Vereerstraeten P, Dupont E, Andrien M, De Pauw L, Kinnaert P, Toussaint C. Donor-recipient (DR) antigen combinations in cadaver renal graft survival: a new approach to recipient selection. Transplant Proc. 19:1987;3647-3650.
20. Roelen DL, van Bree SP, van Beelen E, Schanz U, Rood JJv, Claas FH. Cytotoxic T lymphocytes against HLA-B antigens are less naive than cytotoxic T lymphocytes against HLA-A antigens. Transplantation. 57:1994;446-450.
21. Zantvoort FA, Thorogood J, D'Amaro J, et al. The relevance of HLA-A matching in first unrelated renal allografts. Transplantation. 61:1996;841-844.
22. Maruya E, Takemoto S, Terasaki PI. HLA matching: identification of permissible HLA mismatches. Terasaki PI, Cecka JM. Clinical transplants 1993. 1993;511-520 UCLA Tissue Typing, Los Angeles CA.
23. Doxiadis IIN, Smits JMA, Schreuder GMT, et al. Association between specific HLA combinations and probability of kidney allograft loss: the taboo concept. Lancet. 348:1996;850-853.
24. Doxiadis II, Smits JM, Stobbe I, et al. Taboo HLA mismatches in cadaveric renal transplantation: definition, analysis and possible implications. Transplant Proc. 28:1996;224.
25. Alfani D, Pretagostini R, Rossi M, et al. Analysis of 160 consecutive living unrelated kidney transplants: 1983-1997. Transplant Proc. 29:1997;3399-3401.
26. Bradley JA, Mason DW, Morris PJ. Evidence that rat renal allograft are rejected by cytotoxic T cells and not by nonspecific effectors. Transplantation. 39:1985;169-175.
27. Mast BJvd, Viëtor HE, Meer-Prins EMWvd, et al. Modulation of the T cell compartment by blood transfusion. Effect on cytotoxic and helper T lymphocyte precursor frequencies and T cell receptor V beta usage. Transplantation. 63:1997;1145-1154.
28. Bouma GJ, van der Meer-Prins PM, van Bree FP, van Rood JJ, Claas FH. Determination of cytotoxic T-lymphocyte precursor frequencies using europium labeling as a nonradioactive alternative to labeling with chromium-51. Hum Immunol. 35:1992;85-92.
29. Detrisac CJ, Sens MA, Garvin AJ, Spicer SS, Sens DA. Tissue culture of human kidney epithelial cells of proximal tubule origin. Kidney Int. 25:1984;383.
30. Deckers JGM, Boonstra JG, van der Kooij SW, Daha MR, van der Woude FJ. Tissue-specific characteristics of cytotoxic graft infiltrating T cells during real allograft rejection. Transplantation. 64:1997;178.
31. Strijbosch LWG, Buurman WA, Does RJMM, Zinken PH, Groenewegen G. Limiting dilution assays: experimental design and statistical analysis. J Immunol Methods. 97:1987;133-140.
32. Rammensee H-G, Friede T, Stevanovic S. MHC ligands and peptide motifs: first listing. Immunogenetics. 41:1995;178-228.
33. van der Burg SHvd, Ras E, Drijfhout JW, et al. An HLA class I peptide-binding assay based on competition for binding to class I molecules on intact human B-cells: Identification of conserved HIV-1 polymerase peptides binding to HLA-A*0301. Hum Immunol. 44:1995;189-198.
34. Burrows SR, Rodda SJ, Suhrbier A, Geysen HM, Moss DJ. The specificity of recognition of a cytotoxic T lymphocyte epitope. Eur J Immunol. 22:1992;191-195.
35. Steinle A, Reinhardt C, Jantzer A, Schendel DJ. In vivo expansion of HLA-B35 alloreactive T cells sharing homologous T cell receptors: Evidence for maintenance of an oligoclonally dominated allospecificity by persistent stimulation with an autologous MHC/peptide complex. J Exp Med. 181:1995;503-513.
36. Silins SL, Cross SM, Krauer KG, Moss DJ, Schmidt CW, Misko IS. A functional link for major TCR expansions in healthy adults caused by persistent Epstein-Barr virus infection. J Clin Invest. 102:1998;1551-1558.
37. Lombardi G, Sidhu S, Daly M, Batchelor JR, Makgoba W, Lechler RI. Are primary alloresponses truly primary? Int Immunol. 2:1990;9-13.
38. Loftus DJ, Chen Y, Covell DG, Engelhard VH, Appella E. Differential contact of disparate class I/peptide complexes as the basis for epitope cross-recognition by a single T cell receptor. J Immunol. 158:1997;3651-3658.
39. Burrows SR, Khanna R, Silins SL, Moss DJ. The influence of antiviral T-cell responses on the alloreactive repertoire. Immunol Today. 20:1999;203-207.
40. Udalova IA, Nedospasov SA, Webb GC, Chaplin DD, Turetskaya RL. Highly informative typing of the human TNF locus using six adjacent polymorphic markers. Genomics. 16:1993;180-186.
41. Verjans GMGM, van der Linden SM, van Eys GJJM, de Waal LP, Kilstra A. Restriction fragment length polymorphism of the tumor necrosis factor region in patients with ankylosing spondylitis. Arthr Rheum. 34:1991;486-489.
42. Wichelow CE, Hitman GA, Raafat I, Bottazzo GF, Sachs JA. The effect of TNF*B gene polymorphism on the TNF-alpha and -beta secretion levels in patients with insulin-dependent diabetis mellitus and healthy controls. Eur J Immunogenet. 23:1996;425-435.
43. Weissensteiner Th, Lanchbury JS. TNFB polymorphisms characterize three lineages of TNF region microsatellite haplotypes. Immunogenetics. 47:1997;6-16.
44. Wilson GA, de Vries N, Pociot F, di Giovine FS, van der Putte LBA, Duff GW. An allelic polymorphism within the human tumor necrosis factor alpha promotor region is strongly associated with HLA-A1, -B8, and -DR3 alleles. J Exp Med. 177:1993;557-560.
45. Hanifi Moghaddam P, Zwinderman A, Kazemi M, et al. D6s TNFa microsatellite locus correlates with CTLp frequency in unrelated bone marrow donor-recipient pairs. Hum Immunol. 59:1998;295-301.